Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
SEC Accession No. 0001193125-19-115862
Filing Date
2019-04-24
Accepted
2019-04-24 08:31:03
Documents
5
Effectiveness Date
2019-04-24

Document Format Files

Seq Description Document Type Size
1 DEFA14A d738637ddefa14a.htm DEFA14A 32017
2 GRAPHIC g738637dsp002.jpg GRAPHIC 1750
3 GRAPHIC g738637dsp003.jpg GRAPHIC 7619
4 GRAPHIC g738637dsp003a.jpg GRAPHIC 1762
5 GRAPHIC g738637dsp004.jpg GRAPHIC 1748
  Complete submission text file 0001193125-19-115862.txt   51345
Mailing Address 210 EAST GRAND AVENUE SOUTH SAN FRANCISCO CA 94080
Business Address 210 EAST GRAND AVENUE SOUTH SAN FRANCISCO CA 94080 (650) 457-2700
Allogene Therapeutics, Inc. (Filer) CIK: 0001737287 (see all company filings)

EIN.: 823562771 | Fiscal Year End: 1231
Type: DEFA14A | Act: 34 | File No.: 001-38693 | Film No.: 19762682
SIC: 2836 Biological Products, (No Diagnostic Substances)